TrialCNS drugs2019

A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.

Zeinab Gharaylou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.